Updated Jul 16, 2026
Prasad Raju has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.10M.

Raju Prasad is the Chief Financial Officer of CRISPR Therapeutics AG, a company specializing in gene editing technologies. He has been involved in the financial operations of the company, contributing to its growth in the biotechnology sector.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-24 | CRSP | CRISPR Therapeutics AG | S — Open-market sale | 3.7K | $46.78 | $173K |
| 2026-03-24 | CRSP | CRISPR Therapeutics AG | M — Option exercise | 6.2K | — | |
| 2026-03-17 | CRSP | CRISPR Therapeutics AG | G — Bona-fide gift | 750 | $0.00 | |
| 2026-03-17 | CRSP | CRISPR Therapeutics AG | S — Open-market sale | 4.0K | $48.26 | $194K |
| 2026-03-17 | CRSP | CRISPR Therapeutics AG | S — Open-market sale | 5.8K | $48.26 | $282K |
| 2026-03-17 | CRSP | CRISPR Therapeutics AG | M — Option exercise | 6.9K | — | |
| 2026-03-17 | CRSP | CRISPR Therapeutics AG | M — Option exercise | 10.0K | — | |
| 2026-01-26 | CRSP | CRISPR Therapeutics AG | S — Open-market sale [10b5-1] | 35.0K | $60.19 | $2.10M |
| 2026-01-26 | CRSP | CRISPR Therapeutics AG | M — Option exercise [10b5-1] | 35.0K | $45.15 | $1.58M |
| 2026-01-08 | CRSP | CRISPR Therapeutics AG | S — Open-market sale [10b5-1] | 5.8K | $60.21 | $347K |
| 2026-01-08 | CRSP | CRISPR Therapeutics AG | S — Open-market sale [10b5-1] | 5.0K | $60.00 | $300K |
| 2026-01-08 | CRSP | CRISPR Therapeutics AG | S — Open-market sale [10b5-1] | 18.9K | $60.18 | $1.14M |
| 2026-01-08 | CRSP | CRISPR Therapeutics AG | M — Option exercise [10b5-1] | 6.3K | $44.31 | $281K |
| 2026-01-08 | CRSP | CRISPR Therapeutics AG | M — Option exercise [10b5-1] | 23.4K | $45.15 | $1.05M |
| 2025-12-23 | CRSP | CRISPR Therapeutics AG | S — Open-market sale [10b5-1] | 1.0K | $56.89 | $57K |
| 2025-12-23 | CRSP | CRISPR Therapeutics AG | S — Open-market sale [10b5-1] | 5.5K | $56.33 | $308K |
| 2025-12-23 | CRSP | CRISPR Therapeutics AG | S — Open-market sale [10b5-1] | 3.5K | $55.10 | $194K |
Raju Prasad is the Chief Financial Officer of CRISPR Therapeutics AG, a company specializing in gene editing technologies. He has been involved in the financial operations of the company, contributing to its growth in the biotechnology sector.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 10 open-market sales ($5.10M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Prasad Raju profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.